160 related articles for article (PubMed ID: 15646066)
21. A decade of HIV-1 drug resistance in the United States: trends and characteristics in a large protease/reverse transcriptase and co-receptor tropism database from 2003 to 2012.
Paquet AC; Solberg OD; Napolitano LA; Volpe JM; Walworth C; Whitcomb JM; Petropoulos CJ; Haddad M
Antivir Ther; 2014; 19(4):435-41. PubMed ID: 24518099
[TBL] [Abstract][Full Text] [Related]
22. HIV-1 antiretroviral drug therapy.
Arts EJ; Hazuda DJ
Cold Spring Harb Perspect Med; 2012 Apr; 2(4):a007161. PubMed ID: 22474613
[TBL] [Abstract][Full Text] [Related]
23. Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.
Bazzoli C; Jullien V; Le Tiec C; Rey E; Mentré F; Taburet AM
Clin Pharmacokinet; 2010; 49(1):17-45. PubMed ID: 20000887
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A
J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
[TBL] [Abstract][Full Text] [Related]
25. An introduction to nucleoside and nucleotide analogues.
Squires KE
Antivir Ther; 2001; 6 Suppl 3():1-14. PubMed ID: 11678469
[TBL] [Abstract][Full Text] [Related]
26. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein.
Wang X; Nitanda T; Shi M; Okamoto M; Furukawa T; Sugimoto Y; Akiyama S; Baba M
Biochem Pharmacol; 2004 Oct; 68(7):1363-70. PubMed ID: 15345326
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy.
Pavie J; Porcher R; Torti C; Medrano J; Castagna A; Valin N; Rusconi S; Ammassari A; Ghosn J; Delaugerre C; Molina JM;
J Antimicrob Chemother; 2011 Oct; 66(10):2372-8. PubMed ID: 21821627
[TBL] [Abstract][Full Text] [Related]
28. Genotype and antiretroviral drug resistance of human immunodeficiency virus-1 in Saudi Arabia.
Jamjoom GA; Azhar EI; Madani TA; Hindawi SI; Bakhsh HA; Damanhouri GA
Saudi Med J; 2010 Sep; 31(9):987-92. PubMed ID: 20844809
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
Imaz A; Llibre JM; Mora M; Mateo G; Camacho A; Blanco JR; Curran A; Santos JR; Caballero E; Bravo I; Gayá F; Domingo P; Rivero A; Falcó V; Clotet B; Ribera E
J Antimicrob Chemother; 2011 Feb; 66(2):358-62. PubMed ID: 21172789
[TBL] [Abstract][Full Text] [Related]
30. Accumulation of drug resistance and loss of therapeutic options precede commonly used criteria for treatment failure in HIV-1 subtype-C-infected patients.
Barth RE; Aitken SC; Tempelman H; Geelen SP; van Bussel EM; Hoepelman AI; Schuurman R; Wensing AM
Antivir Ther; 2012; 17(2):377-86. PubMed ID: 22297391
[TBL] [Abstract][Full Text] [Related]
31. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.
de Mulder M; Yebra G; Martín L; Prieto L; Mellado MJ; Rojo P; Muñoz-Fernández MÁ; Jiménez de Ory S; Ramos JT; Holguín A;
J Antimicrob Chemother; 2011 Oct; 66(10):2362-71. PubMed ID: 21810838
[TBL] [Abstract][Full Text] [Related]
32. Role of lymphocyte multidrug resistance protein 1 in HIV infection: expression, function, and consequences of inhibition.
Lucia MB; Savarino A; Straface E; Golotta C; Rastrelli E; Matarrese P; Rutella S; Malorni W; Cauda R
J Acquir Immune Defic Syndr; 2005 Nov; 40(3):257-66. PubMed ID: 16249698
[TBL] [Abstract][Full Text] [Related]
33. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
34. The intracellular pharmacology of antiretroviral protease inhibitors.
Ford J; Khoo SH; Back DJ
J Antimicrob Chemother; 2004 Dec; 54(6):982-90. PubMed ID: 15537695
[TBL] [Abstract][Full Text] [Related]
35. Antiretroviral resistance patterns and factors associated with resistance in adult patients failing NNRTI-based regimens in the Western Cape, South Africa.
van Zyl GU; van der Merwe L; Claassen M; Zeier M; Preiser W
J Med Virol; 2011 Oct; 83(10):1764-9. PubMed ID: 21837793
[TBL] [Abstract][Full Text] [Related]
36. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
Venturi G; Catucci M; Romano L; Corsi P; Leoncini F; Valensin PE; Zazzi M
J Infect Dis; 2000 Feb; 181(2):740-5. PubMed ID: 10669367
[TBL] [Abstract][Full Text] [Related]
37. HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).
Geleziunas R; Gallagher K; Zhang H; Bacheler L; Garber S; Wu JT; Shi G; Otto MJ; Schinazi RF; Erickson-Viitanen S
Antivir Chem Chemother; 2003 Jan; 14(1):49-59. PubMed ID: 12790516
[TBL] [Abstract][Full Text] [Related]
38. New anti-HIV agents and targets.
De Clercq E
Med Res Rev; 2002 Nov; 22(6):531-65. PubMed ID: 12369088
[TBL] [Abstract][Full Text] [Related]
39. New drugs.
Pozniak A
J HIV Ther; 2008 Jun; 13(2):27-33. PubMed ID: 18953271
[No Abstract] [Full Text] [Related]
40. Pharmacological considerations in antiretroviral therapy.
Sommadossi JP
Antivir Ther; 1998; 3 Suppl 4():9-12. PubMed ID: 10723503
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
